Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study - 24/04/13
, Oh Sang Kwon, MD a, Je Ho Yeon, MD a, Hyo Seung Shin, MD a, Byung Yoon Kim, MD a, Byung In Ro, MD b, Han Kyong Cho, MD b, Woo Young Sim, MD c, Bark Lynn Lew, MD c, Won-Soo Lee, MD d, e, Hwa Young Park, MD d, Seung Phil Hong, MD d, Jae Hong Ji, MD d
Reprint requests: Hee Chul Eun, MD, Department of Dermatology, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehang-ro, Jongno-gu, Seoul, 110-744 Korea.Abstract |
Background |
Dutasteride (Avodart) is a dual inhibitor of both type I and type II 5 alpha reductases, and thus inhibits conversion of testosterone to dihydrotestosterone, a key mediator of male pattern hair loss.
Objectives |
The aim of this randomized double-blind phase III study was to compare the efficacy, safety, and tolerability of dutasteride (0.5 mg) and placebo for 6 months of treatment in male patients with male pattern hair loss.
Methods |
A total of 153 men, 18 to 49 years old, were randomized to receive 0.5 mg of dutasteride or placebo daily for 6 months. Efficacy was evaluated by the change of hair counts, subject assessment, and photographic assessment by investigators and panels.
Results |
Mean change of hair counts from baseline to 6 months after treatment start was an increase of 12.2/cm2 in dutasteride group and 4.7/cm2 in placebo group and this difference was statistically significant (P = .0319). Dutasteride showed significantly higher efficacy than placebo group by subject self-assessment and by investigator and panel photographic assessment. There was no major difference in adverse events between two groups.
Limitations |
The study was limited to 6 months.
Conclusions |
This study clearly showed that 0.5 mg of dutasteride improved hair growth and was relatively well tolerated for the treatment of male pattern hair loss.
Le texte complet de cet article est disponible en PDF.Key words : androgenetic alopecia, dutasteride, male pattern hair loss, treatment
Abbreviations used : 5AR, DHT, HGI, MPHL
Plan
| Supported by GlaxoSmithKline. |
|
| Conflicts of interest: None declared. |
Vol 63 - N° 2
P. 252-258 - août 2010 Retour au numéro
Article précédent
- Acral lesions in tuberous sclerosis complex: Insights into pathogenesis
- Capt Shelley L. Aldrich, Chien-Hui Hong, Leslie Groves, Cara Olsen, Joel Moss, Thomas N. Darling
- Leukocytoclastic vasculitis and necrolytic acral erythema in patients with hepatitis C infection: Do viral load and viral genotype play a role?
- Mohammad A. El-Darouti, Heba M. Mashaly, Eman El-Nabarawy, Amal M. Eissa, Mona R.E. Abdel-Halim, Marwa M.T. Fawzi, Nermine H. El-Eishi, Sherine O. Tawfik, Naglaa S. Zaki, Anoud Z. Zidan, Marwa Fawzi, Mohammad Abdelaziz, Mai M.T. Fawzi, Olfat G. Shaker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?